Developing Novel Treatments for Rare Disorders: A Look at MPS I with Dr. Emil Kakkis

 

About this Podcast: 

In this episode, WCG’s President of Patient Advocacy, Steve Smith, talks with Emil Kakkis, MD, PhD, Chief Executive Officer of Ultragenyx Pharmaceuticals and President of the non-profit EveryLife Foundation for Rare Diseases organization. Known for his work in developing an enzyme replacement therapy for the rare disorder MPS I and his connection to the Ryan Foundation, Dr. Kakkis shares with us his experiences in being involved in bringing drugs to market and forming relationships with patients along the way.

About the Author

Steve Smith | President, Patient Advocacy, WCG

Steve Smith is a seasoned patient advocate with an extensive career in software, consulting, process transformation, health care systems and patient-focused drug development. He joined WCG as President Patient Advocacy in 2019 inspired by the incredible value to patients embedded in the wide range of WCG solutions that reduce the time and cost of clinical trials.

Visit Website More Content by Steve Smith | President, Patient Advocacy, WCG
Previous Post
An Inside Look at Angelman Syndrome Rare Disease with Advocate Amanda Moore
An Inside Look at Angelman Syndrome Rare Disease with Advocate Amanda Moore

Next Post
Blazing New Trails in Rare Disease & CNS Clinical Studies: An Interview with Dr. Mark Opler
Blazing New Trails in Rare Disease & CNS Clinical Studies: An Interview with Dr. Mark Opler